Promoters for Heterologous Gene Expression EP3294890A1

EPO published international patent application EP3294890A1 under the C12N classification, covering promoters used for expressing heterologous genes in biotechnological applications. The application names Children's Medical Research Institute and The Sydney Children's Hospitals Network as applicants, with inventors Logan, Alexander, and Dane. The filing seeks protection across 30 designated contracting states including all major European patent jurisdictions.

Biotechnology firms and research institutions developing gene therapy vectors, recombinant protein expression systems, or synthetic biology platforms should review the published claims for potential freedom-to-operate implications. While patent grants do not create immediate compliance obligations, the published claims define the scope of intellectual property rights that may restrict commercial development activities in related promoter technologies.